- Home
- RNG vs QURE Comparison
RNG vs QURE Comparison
Compare RNG & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNG | QURE |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | RNG | QURE |
|---|---|---|
| Price | $76.22 | $38.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 14 |
| Target Price | $33.58 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ 176.19 | 29.67 |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $2,515,142,000.00 | $13,107,000.00 |
| Revenue This Year | $5.56 | $126.12 |
| Revenue Next Year | $4.56 | $200.43 |
| P/E Ratio | $99.78 | ★ N/A |
| Revenue Growth | ★ 4.78 | N/A |
| 52 Week Low | $24.14 | $8.73 |
| 52 Week High | $81.90 | $71.50 |
Technical Indicators
Market Signals| Indicator | RNG | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 31.13 |
| Support Level | $67.97 | $35.34 |
| Resistance Level | $77.95 | $51.09 |
| Average True Range (ATR) | 3.21 | 2.07 |
| MACD | 0.05 | -0.76 |
| Stochastic Oscillator | 61.01 | 14.47 |
Price Performance
Historical ComparisonAbout RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.